ADS-ADEA 2015* Alana Philips
Novo Nordisk, NSW, Australia
- This delegate is presenting an abstract at this event.
- Trade
Presentations this author is a contributor to:
Liraglutide 3.0 mg for weight management in obese/overweight adults with type 2 diabetes: Results from the SCALE Diabetes 56-week randomised, double-blind, placebo-controlled trial (#9)
9:15 AM
John Prins
ADS Clinical Orals: Obesity
Weight loss with liraglutide 3.0 mg is associated with improved health-related quality of life (HRQoL) and treatment satisfaction in overweight or obese adults with type 2 diabetes (T2D): The SCALE Diabetes randomised, double-blind, placebo-controlled 56-week trial (#304)
2:00 PM
Trisha O'Moore-Sullivan
ADS Clinical Poster Viewing: Treatment
Efficacy and safety of liraglutide 3.0 mg and 1.8 mg in weight loss responders from overweight/obese adults with type 2 diabetes (T2D): A subgroup analysis of the SCALE Diabetes trial (#306)
2:00 PM
Trisha O'Moore-Sullivan
ADS Clinical Poster Viewing: Treatment